Answer
Pirtobrutinib, a moderate BCRP inhibitor, increased rosuvastatin AUC by 140% and Cmax by 146%, so caution is advised when they are co-administered.
Sources for this answer
- Jaypirca 50mg, 100mg film-coated tabletsEli Lilly and Company Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 4Document updated
Sources checked